Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
Customize your policy alerts
Sign up for Capital Bluecross Policy MP 9.041 alerts
Get alerted when Policy MP 9.041 changes without checking for updates manually.
Monitor payer policy activity
Clinical coverage policy for autologous and allogeneic hematopoietic cell transplantation (HCT) for childhood and adult acute lymphoblastic leukemia (ALL), specifying when HCT is considered medically necessary and outlining risk stratification and conditioning considerations for providers and prior authorization reviewers.
No material clinical or coverage changes in this revision.
Coverage Criteria for Hematopoietic Cell Transplantation (HCT) in ALL
inv-01: Childhood ALL — Covered Indications
Covered when ANY of the following are met:
See Policy Guidelines for high-risk definitions.
inv-02: Adult ALL — Covered and Not Covered Indications
Covered when specified criteria are met; investigational where noted:
See Policy Guidelines for medical reasons.
Requests for these indications may be denied as investigational per policy.
inv-03: Indications supported by evidence
Covered when evidence supports meaningful improvement in net health outcome for these patient groups:
Supported by RCTs, systematic reviews, and ASBMT position statements.
inv-04: Insufficient evidence
Not enough evidence to determine benefit:
Evidence reviews identified only small case series with short-term follow-up.
Autologous hematopoietic cell transplantation (HCT) for adults with acute lymphoblastic leukemia (ALL) in second or greater complete remission or with refractory disease is designated investigational. The policy states there is insufficient evidence to support a general conclusion that autologous HCT improves health outcomes in these adult patient groups, and therefore such requests may be denied as investigational.
The policy does not list broad categorical exclusions, but it implies that patients who are unable to tolerate conditioning regimens (for example, myeloablative conditioning) because of age, comorbidities, or poor performance status are not candidates for those higher‑intensity approaches. In such cases, conditioning intensity and overall transplant candidacy should be documented and alternatives (including reduced‑intensity conditioning) considered per the Policy Guidelines.
No explicit exclusions are stated in the provided policy history and administrative notes. Policy updates and consensus reviews are documented, but they do not add or specify new blanket exclusions in the cited sections.
For patients who relapse after a prior autologous HCT and are being considered for allogeneic HCT, the evidence is limited to small case series with short follow‑up. The policy concludes that the available data are insufficient to determine benefit for allo‑HCT in this setting, and therefore effectiveness is not established.
The provided policy history and administrative sections do not contain explicit statements using the phrase ‘not medically necessary’ for specific scenarios in the cited chunks. Operational and administrative notes record reviews and reference updates but do not add new not‑medically‑necessary declarations in these excerpts.
Conditioning Regimens and Intensity
| Regimen | Indication / patient selection | Coverage stance |
|---|---|---|
| Reduced-intensity conditioning (RIC) allogeneic HCT | Patients unable to tolerate standard myeloablative conditioning due to age (typically >60 years) or comorbidities (e.g., liver or kidney dysfunction, generalized debilitation, prior intensive chemotherapy, low Karnofsky Performance Status) | Reduced-intensity conditioning allogeneic HCT may be considered medically necessary when patient cannot tolerate myeloablative conditioning |
| Approach | Description | When to use / recommendation |
|---|---|---|
| Myeloablative conditioning (conventional) | Intense regimens using cytotoxic agents (e.g., cyclophosphamide, busulfan) with or without high-dose radiotherapy intended to cause marrow ablation; provides tumor eradication plus graft-versus-malignancy effect but with higher treatment-related toxicity | Recommended when patient’s health status is sufficient to tolerate full myeloablative conditioning |
| Reduced-intensity conditioning (RIC) | Pretransplant regimens using lower doses of cytotoxic drugs or less intense radiotherapy intended to be nonmyeloablative to reduce treatment-related morbidity and nonrelapse mortality while enabling graft-versus-malignancy effects; intensity ranges from near-myeloablative to minimally myeloablative with lymphoablation | Consider for patients who cannot tolerate full myeloablative conditioning due to age, comorbidity, or poor performance status |
| Study / source | Population & comparison | Key point cited |
|---|---|---|
| Abdul Wahid SF et al., meta-analysis (Stem Cells Dev. 2014) [cited] | Adults with acute leukemias (including AML and ALL): compared reduced-intensity vs myeloablative conditioning | Comparative syntheses examining RIC versus myeloablative conditioning summarized outcomes across studies |
| Mohty M et al., retrospective EBMT study (Haematologica. 2008) [cited] | Adult patients with ALL receiving reduced-intensity conditioning allogeneic SCT (retrospective cohort) | Reports RIC as a potential therapeutic approach for adults with ALL in remission |
| Pulsipher MA et al., Pediatric Blood and Marrow Transplant Consortium Study ONC0313 (Blood. 2009) [cited] | Pediatric patients ineligible for myeloablative therapy receiving reduced-intensity allogeneic transplantation | Provides evidence for RIC use in pediatric patients ineligible for myeloablative regimens |
Line of Therapy Considerations
inv-31: first-line
Children: see Policy Guidelines; Adults: see Policy Guidelines.
inv-32: salvage
inv-33: first-line
Supported by RCTs, systematic reviews, and ASBMT position statements.
inv-34: salvage
inv-35: first-line
References include meta-analyses and randomized trials.
Biomarkers and Genetic Risk Factors
Procedure and Diagnosis Codes
| S2140 | listed in procedure codes |
| S2142 | listed in procedure codes |
| S2150 | listed in procedure codes |
| 38204 | listed in procedure codes |
| 38205 | listed in procedure codes |
| 38206 | listed in procedure codes |
| 38207 | listed in procedure codes |
| 38208 | listed in procedure codes |
| 38209 | listed in procedure codes |
| 38210 | listed in procedure codes |
| C91.00 | Acute lymphoblastic leukemia not having achieved remission |
| C91.01 | Acute lymphoblastic leukemia, in remission |
| C91.02 | Acute lymphoblastic leukemia, in relapse |
Provider Actions, Prior Authorization, and Documentation
Obtain prior authorization to confirm indication and conditioning rationale
Prior authorization is required to confirm the indication for HCT (e.g., first complete remission with high-risk features, second or greater remission, refractory disease, or relapse after prior autologous HCT) and to document donor type and conditioning approach, including rationale for reduced-intensity conditioning when used.
- Confirm line of therapy and remission status (CR1 with high-risk features, CR2+, refractory, or relapse after prior autologous HCT).
- Document donor type (autologous vs allogeneic) and HLA matching details.
- Provide rationale for conditioning approach and, if applicable, reasons reduced-intensity conditioning is chosen.
Include listed procedure and diagnosis codes in authorization submissions
Use the procedure and diagnosis codes listed in the policy’s coding section when submitting prior authorization requests to support medical necessity determinations.
Summary: prior authorization requirement (no extra operational steps listed)
Prior authorization is required as described in the policy; no additional explicit operational prior authorization steps are specified in these sections of the document.
- Follow standard prior authorization processes; the policy text does not add extra operational submission steps beyond documentation of indication and coding.
No step therapy sequencing specified
The policy does not specify any step therapy sequencing or required prior treatments before HCT.
- No mandated prior disease-modifying therapy sequence is described in these policy sections.
No step therapy requirements in this section
No step therapy requirements for HCT are specified in the policy text cited.
- Coverage is determined by member benefit, eligibility, and medical necessity rather than a step-therapy algorithm in this policy.
No step therapy requirements described
There are no step therapy requirements described in the provided policy text for HCT.
- Policy history and administrative notes do not introduce step therapy sequencing.
Include disease status, risk factors, donor match, and conditioning details in documentation
Documentation submitted for authorization should include disease status (remission number; relapsed or refractory status), risk-stratification factors, donor matching, and conditioning-intensity rationale to support medical necessity.
- Specify remission status (CR1 with high-risk features, CR2+, refractory, or relapse).
- Provide risk factors used for stratification (age, WBC, genetic abnormalities such as t(9;22) or t(4;11), MRD status) where applicable.
- Include donor HLA matching information and chosen conditioning intensity (myeloablative vs reduced-intensity) with justification.
Provide listed codes and supporting documentation with requests
Coding and documentation should reference the policy’s listed procedure and diagnosis codes and the policy note that code identification does not by itself guarantee coverage.
Policy history provided; no additional operational steps
Policy history and administrative notes are provided but do not add specific operational steps for providers beyond the policy’s clinical and documentation requirements.
- Review policy history for updates, but follow the medical necessity and documentation requirements stated elsewhere in the policy for authorizations.
Investigational: autologous HCT for adult CR2+ or refractory disease — potential denial risk
Requests for autologous HCT in adults for second or greater remission or refractory disease may be denied as investigational under this policy.
- Autologous HCT is explicitly stated as investigational for adult ALL in second or greater remission or refractory disease due to insufficient evidence of benefit.
- Provide evidence or rationale if seeking approval for such cases, recognizing the policy stance.
Verify eligibility, benefits, and medical necessity before proceeding
Coverage and payment are subject to the member’s benefit program, eligibility on the date of service, and a determination that the services are medically necessary and appropriate.
- Verify member eligibility and benefit coverage prior to scheduling/transplant.
- Ensure documentation demonstrates medical necessity per policy criteria.
No additional explicit denial triggers listed in these sections
No explicit denial triggers beyond the policy’s stated investigational stance and standard eligibility/medical necessity determinations are identified in these sections.
- Use the policy clinical criteria and documentation requirements to reduce risk of denial; policy history does not add other denial triggers.
Definitions
Background and Rationale
Acute lymphoblastic leukemia (ALL) is a heterogeneous disease with distinct biologic subtypes and prognostic factors that guide risk‑adapted management. Hematopoietic cell transplantation (HCT) — either autologous or allogeneic — is used selectively as part of that risk‑adapted strategy: for example, HCT may be considered for children and adults in first complete remission when at high risk of relapse, for patients in second or greater remission, and for relapsed or refractory disease in appropriate candidates. The balance of potential benefit (reduced relapse) and harms (higher treatment‑related mortality) is emphasized in the evidence summaries and underlies the policy’s differentiated recommendations.
Evidence Summary and References
The policy cites multiple primary studies, meta‑analyses, and guideline documents to support its conclusions. Representative references include randomized controlled trials and systematic reviews (for example, Cochrane and meta‑analyses), retrospective series of reduced‑intensity conditioning, and guideline sources such as NCCN and ASBMT/ASTCT guidance. These references are listed in the policy’s reference section to support the stated evidence summaries and recommendations.
Where evidence supports clinically meaningful improvement in net health outcome, the policy identifies first‑line and salvage indications for HCT. Examples include: autologous or allogeneic HCT for children with high‑risk ALL in first complete remission or with relapsed disease; autologous HCT for adults with high‑risk ALL in first complete remission when the patient can tolerate the procedure; and myeloablative allogeneic HCT for adults with ALL who can tolerate the regimen. The policy also recognizes reduced‑intensity conditioning (RIC) allogeneic HCT as an option for patients in complete marrow and extramedullary first or second remission who cannot tolerate standard myeloablative conditioning.
Revision History
Policy effective date for MP 9.041 updated to 2026-05-01.
Consensus review completed with no change to policy intent; policy updated.
Consensus review completed with no change to policy stance; policy updated.
Administrative update removing NCCN statement.
Consensus review completed with no change to policy statement; new references added.
Consensus review completed with no change to policy statement; new definitions and references added.
Language added during consensus review; references added with no change to policy statement.
Consensus review completed with no change to policy statement; policy guidelines, background, rationale, and references updated.
Consensus review completed with no change to policy statements; references updated and coding reviewed.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.